Natixis Advisors L.P. decreased its stake in Sanofi (NASDAQ:SNY - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,465,762 shares of the company's stock after selling 62,527 shares during the period. Natixis Advisors L.P. owned 0.10% of Sanofi worth $122,622,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rise Advisors LLC raised its position in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company's stock valued at $25,000 after purchasing an additional 251 shares during the last quarter. Salem Investment Counselors Inc. purchased a new stake in Sanofi in the 4th quarter valued at $27,000. Venturi Wealth Management LLC raised its position in Sanofi by 163.5% in the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company's stock valued at $27,000 after purchasing an additional 332 shares during the last quarter. McIlrath & Eck LLC raised its position in Sanofi by 143.3% during the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company's stock worth $30,000 after buying an additional 361 shares during the last quarter. Finally, CNB Bank purchased a new position in Sanofi during the 3rd quarter worth $39,000. Hedge funds and other institutional investors own 10.04% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on SNY. StockNews.com downgraded shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, February 27th. TheStreet downgraded shares of Sanofi from a "b" rating to a "c" rating in a research report on Friday, February 9th. Finally, Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an "equal weight" rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $55.00.
Check Out Our Latest Analysis on SNY
Sanofi Price Performance
Shares of SNY traded down $0.57 during trading hours on Thursday, reaching $49.46. The company had a trading volume of 4,596,559 shares, compared to its average volume of 2,047,753. The firm has a 50 day simple moving average of $47.86 and a 200-day simple moving average of $48.26. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $125.11 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 1.37 and a beta of 0.61. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.93.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts' expectations of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. Research analysts expect that Sanofi will post 4.12 earnings per share for the current year.
Sanofi Increases Dividend
The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. This represents a yield of 2.98%. This is a boost from Sanofi's previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi's dividend payout ratio is presently 69.35%.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
